GBIO Generation Bio Corp: Rentabilitas operasi

Generation Bio Co. - logo grafis emiten GBIO

Generation Bio Co. (GBIO) is developing non-viral DNA delivery methods for the treatment of eye and liver pathologies. Future revenues are based on the commercialization of the ceDNA platform, which enables repeated treatment of genetic diseases. The company is currently in the pre-commercial stage, meaning external financing only serves to mitigate capital expenditure. The quarterly operating margin clearly demonstrates efficiency trends, where the value of -512.50 expresses the metric level.

GBIO - Tingkat bathi operasi Generation Bio Co ing rentang 04.07.2022 - 21.02.2026

Rincian metrik lan analitis perusahaan Generation Bio Co. (GBIO)

- rega saham lan konsensus proyeksi valuasi:
- data kapitalisasi saham perusahaan:
Analisis wiwitan perusahaan:Generation Bio, GBIO
Barang utama Generation Bio Corp

For Generation Bio Co. (GBIO), which protects its unique DNA platforms with patents, the negative margin reflects a stage of capital-intensive development under strict FDA oversight. An analysis of operating profit margins allows for an assessment of the operating income share after deducting all expenses, excluding the impact of debt load and taxes, which confirms the strategic priority of scaling technologies over current profitability.

Pesaing Generation Bio Co. (GBIO)

Margin dodolan operasi TEM|QGEN - Tingkat bathi adhedhasar bathi operasi|Margin operasi IONS|RGEN - Rentabilitas dodolan operasi|Rentabilitas operasi Avidity RNA|Margin operasi CRISPR Therapeutics Corp CRSP|GeneDx Corp - Margin operasi|Ultragenyx Pharma (RARE) - Margin dodolan operasi|beamtx.com (BEAM) - Rentabilitas operasi|SRPT: Rasio bathi operasi|Margin dodolan operasi TWST|TXG - Tingkat bathi adhedhasar bathi operasi|Margin operasi NTLA|Rentabilitas kegiatan operasi Stoke Therapeutics|Rentabilitas operasi BioLife Solutions BLFS|Wave Life Sciences (WVE) - Rentabilitas dodolan operasi|Maze Therapeutics, Inc. - Margin operasi|Rentabilitas kegiatan operasi Sionna Therapeutics, Inc. SION|Prime Medicine Bio (PRME) - Rentabilitas operasi|TSHA: Rasio bathi operasi|Rentabilitas operasi uniQure Pharma|MGTX - Tingkat bathi adhedhasar bathi operasi|Margin operasi RGNX|Rentabilitas operasi SLDB (Solid Biosciences)|Ocugen Corp - Margin dodolan operasi|PACB: Rentabilitas dodolan miturut bathi operasi|benitec.com - Margin operasi|DSGN - Margin operasi|RCKT: Margin operasi|FDMT (4D Molecular Therapeutics Inc) - Rentabilitas operasi|Margin dodolan operasi LXEO|Rentabilitas operasi KRRO|Margin operasi EDIT|SLN - Rentabilitas dodolan operasi|Margin operasi PRQR (ProQR)|CDXS - Margin dodolan operasi|Sangamo Therapeutics Inc. - Margin operasi|NAUT - Margin operasi|MGX: Margin operasi|Margin dodolan operasi Precision BioSciences, Inc.|Rentabilitas operasi Boundless Bio Inc.|Margin dodolan operasi Exicure (XCUR)|Margin operasi IMNN|PHIO (Phio Pharmaceuticals Corp.) - Tingkat bathi operasi|Mustang Bio, Inc. - Margin dodolan operasi|RNAZ - Margin dodolan operasi|BNGO: Margin dodolan operasi|APDN (Applied DNA Sciences Inc) - Rentabilitas dodolan miturut bathi operasi|BLUE (Bluebird Bio) - Margin dodolan operasi|ImmunoPrecise Antibodies Ltd - Tingkat bathi operasi|OMGA (Omega Therapeutics Inc) - Margin operasi|Rentabilitas operasi OMIC|Rentabilitas operasi Regulus Therapeutics Inc. (RGLS)|Margin dodolan operasi Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Margin dodolan operasi|Tingkat bathi operasi TCON|UBX - Rentabilitas operasi